Copyright: Immunotech Applied Science Limited   京ICP备19008112号-1    

Company News
Industry News
THE TWO STANDARDS DRAFTED BY THE IMMUNOTECH BIOPHARM LTD HAVE BEEN UPGRADED TO ZHONGGUANCUN STANDARDS
EAL® WAS GRANTED BREAKTHROUGH THERAPY BY THE CENTER FOR DRUG EVALUATION
The first investigator meeting of Phase I Denocabtagene Ciloleucel Injection (Originally known as RC19D2) successfully held by Immunotech Biopharm Ltd
OBTAINED PHASE I CLINICAL TRIAL APPROVAL FOR DENOCABTAGENE CILOLEUCEL INJECTION (ORIGINALLY KNOWN AS RC19D2, CAR-T-D2, CAR-T-19-DNR)
IMMUNOTECH BIOPHARM LTD DEBUTED AT THE ZHONGGUANCUN FORUM WITH EAL, AND CEO DR. WANG YU GAVE A WONDERFUL PRESENTATION AT THE 2023 ZHONGGUANCUN INTERNATIONAL TECHNOLOGY TRADING CONFERENCE
TALKING ABOUT THE FRONTIERS OF CELL THERAPY INDUSTRY TOGETHER, STANDARDS EMPOWER SUSTAINABLE DEVELOPMENT OF ENTERPRISES
DR. WANG YU, CEO OF YONGTAI BIO-B (06978. HK), ATTENDED THE BOAO FORUM FOR ASIA HEALTH INDUSTRY INTERNATIONAL FORUM - CELL GENE THERAPY AND INDUSTRIALIZATION DEVELOPMENT SUB FORUM AND DELIVERED A KEYNOTE SPEECH
THE COMPANY HELD A GRAND SPEECH ON THE SPIRIT OF THE 20TH CPC NATIONAL CONGRESS
THE COMPANY'S 2022 ESG REPORT STAKEHOLDER SURVEY
SPRING FESTIVAL GREETINGS AND BEST WISHES TO ALL YONGTAI STAFF
Page up
1
2
...
4